Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 2.94%

Ligand Pharmaceuticals reported a significant earnings surprise with an EPS of $1.33, but the stock reacted negatively, dropping 2.94%. The lack of revenue details and guidance may have contributed to investor caution. Management's focus on core operations and R&D investments suggests a long-term growth strategy, but uncertainty remains in the near term.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.33	N/A	+830.07%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed a positive outlook on their core operations despite not providing specific guidance. They are focused on long-term growth through R&D investments.

Management highlighted strong performance in their core business segments.

They noted ongoing investments in research and development.

There was an emphasis on maintaining operational efficiency.

Ligand Pharmaceuticals Beats on EPS, Stock Down 2.94%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 2.94%

Key numbers

Management commentary